iCoreConnect Inc. - Quarter Report: 2012 March (Form 10-Q)

imedicor10q033112.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2012

Commission file number: 000-52765

IMEDICOR, INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		95-4696799
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

523 Avalon Gardens Drive, Nanuet, New York 10954

(Address of principal executive offices) (Zip Code)

(845) 371-7380

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

There were 347,376,527 outstanding shares of the issuer’s Common Stock, $0.001 par value, on May 22, 2012.

Table of Contents

IMEDICOR, INC.

FORM 10-Q QUARTERLY REPORT

FOR THE QUARTER ENDED MARCH 31, 2012

TABLE OF CONTENTS

		Page
Part I Financial Information

Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheet as of March 31, 2012 (unaudited) and June 30, 2011 (audited)	3
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended March 31, 2012 and 2011 (unaudited)	4-5
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2012 and 2011 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	10

Item 4.	Controls and Procedures	15

Part II Other Information

Item 6.	Exhibits	16

	Signatures	17

Table of Contents

PART 1: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

IMEDICOR, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

	3/31/2012			6/30/2011
	(unaudited)			(unaudited)
ASSETS
Current assets:
Cash and cash equivalents - interest bearing	$	29,523		$	18,208
Accounts receivable, net of allowance for doubtful accounts of $-0 - at March 31, 2012 and June 30, 2011		78,480			251,780
Prepaid expenses		30,593			16,108

Total Current Assets		138,596			286,096

Property and equipment, net		-			1,345

Other assets:
Technology & Medical software		1,263,894			2,138,914
		1,263,894			2,138,914

Accounts Receivables in Litigation, net of allowance of $145,630 at March 31, 2012 and $26,000 at June 30, 2011 respectively		409,370			282,000
		409,370			282,000


Total Assets	$	1,811,860		$	2,708,355

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term notes payable	$	3,794,711		$	3,293,079
Accounts payable and accrued expenses		2,331,157			1,804,101
Deferred income		-			182,000

Total Current Liabilities		6,125,868			5,279,180

Total Liabilities		6,125,868			5,279,180

Stockholders' Deficiency
Preferred Stock, Series A par value $.001, authorized 200,000,000 Issued and outstanding 28 and -0- shares as of March 31, 2011 and June 30, 2011, respectively		-			-
Preferred Stock, Series B par value $.001, authorized 200,000,000 Issued and outstanding 18.75 and -0- shares as of March 31, 2012 and June 30, 2011, respectively		-			-
Common stock, par value $.001 per share, authorized 600,000,000 Issued 347,744,934 and 332,744,934 shares; and Outstanding: 347,376,527 and 332,376,527 at March 31, 2012 and June 30, 2011, respectively		347,377			332,377
Additional Paid in Capital		44,074,097			43,839,597
Less: Treasury stock, 368,407 shares at both March 31, 2012 and June 30, 2011		(508,195	)		(508,195	)
Accumulated deficit		(48,227,287	)		(46,234,604	)

Total Stockholders' Deficiency		(4,314,008	)		(2,570,825	)

Total Liabilities and Stockholders' Deficiency	$	1,811,860		$	2,708,355

See notes to Condensed Consolidated Financial Statements (unaudited).

Table of Contents

IMEDICOR, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the			For the
	3 mos ended			3 mos ended
	3/31/2012			3/31/2011
	(unaudited)			(unaudited)

Revenues	$	284,941		$	133,996

Expenses:
Stock issued for fees and services		-			-
Consulting, commissions and travel		322,944			245,962
Operational fees and expenses		130,840			146,926
Professional fees		26,678			46,597
Depreciation and amortization		291,673			512,853
Bad debt expenses		71,630			-
Production, advertising, brochures and public relations		-			38,274

Total Expenses		843,765			990,612

Loss before other expenses		(558,824	)		(856,616	)

Other Income/(Expenses:)
Other income - debt cancellation		-			-
Interest expense		(82,469	)		(84,052	)
Total Other Income/(Expenses)		(82,469	)		(84,052	)

Loss before dividend		(641,293	)		(940,668	)

Dividends related to warrants issued		-			-

Net loss attributable to common shareholders	$	(641,293	)	$	(940,668	)

Net loss per share, available to common stockholders	$	(0.00	)	$	(0.00	)

Weighted average number of shares, basic and diluted		347,376,990			310,774,827

See notes to Condensed Consolidated Financial Statements (unaudited).

Table of Contents

IMEDICOR, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the			For the
	9 mos ended			9 mos ended
	3/31/2012			3/31/2011
	(unaudited)			(unaudited)

Revenues	$	637,295		$	477,119

Expenses:
Stock issued for fees and services		-			545,309
Consulting, commissions and travel		877,250			687,902
Operational fees and expenses		319,513			392,530
Professional fees		46,228			57,492
Depreciation and amortization		876,364			1,545,506
Bad debt expenses		97,630			-
Production, advertising, brochures and public relations		10,015			62,699

Total Expenses		2,227,000			3,291,438

Loss before other expenses		(1,589,705	)		(2,814,319	)

Other Income/(Expenses:)
Other income - debt cancellation		-			91,511
Interest expense		(216,977	)		(403,355	)
Total Other Income/(Expenses)		(216,977	)		(311,844	)

Loss before dividend		(1,806,682	)		(3,126,163	)

Dividends related to warrants issued		-			186,000

Net loss attributable to common shareholders	$	(1,806,682	)	$	(3,312,163	)

Net loss per share, available to common stockholders	$	(0.01	)	$	(0.01	)

Weighted average number of shares, basic and diluted		343,940,626			304,659,743

See notes to Condensed Consolidated Financial Statements (unaudited).

Table of Contents

IMEDICOR, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the			For the
	9 mos ended			9 mos ended
	3/31/2012			3/31/2011
	(unaudited)			(unaudited)
Cash Flows From Operating Activities
Receipts from customers	$	403,344		$	46,829
Payments to suppliers, salaries		(740,184	)		(1,064,165	)
Interest paid		(16,959	)		(196,424	)
Net Cash Used in Operating Activities		(353,799	)		(1,213,760	)

Cash Flows Used in Investing Activities
Purchase of Technology & Medical software		-			(55,000	)
Net Cash Used in Investing Activities		-			(55,000	)

Cash Flows From Financing Activities
Payments on bank note payable		-			(59,181	)
Payments on notes payable		(3,500	)		(15,000	)
Short term loans		368,614			773,297
Sale of common stock		-			484,000
Net Cash Provided by Financing Activities		365,114			1,183,116

Net Increase/(Decrease) in Cash		11,315			(85,644	)

Cash at the Beginning of Period		18,208			86,644

Cash at End of Period	$	29,523		$	1,000

Reconciliation of Net Loss to Net Cash Used in Operating Activities
Net loss	$	(1,806,682	)	$	(3,126,163	)
Adjustments to reconcile net income/(loss) to net cash used in operating activities:
Allowance for bad debt		97,630			-
Depreciation & amortization		876,364			1,545,506
Stock issued for accrued consulting fees		-			545,309
Income derived from relinquishment of debt		-			(91,511	)
Changes in:
Trade receivables		(51,700	)		(426,280	)
Prepaid expenses		(14,485	)		(6,273	)
Accounts payable and accrued expenses		527,056			146,721
Accrued interest payable		200,018			206,931
Deferred income		(182,000	)		(8,000	)
Net Cash Used in Operating Activities	$	(353,799	)	$	(1,213,760	)

Supplemental disclosures:
Schedule of Noncash Investing and Financing Transactions:
Stock issued for fees and services	$	-		$	545,309
Exchanged stock for note payable and accrued interest		63,500			4,651,960
Income derived from relinquishment of debt		-			(91,511	)

See notes to Condensed Consolidated Financial Statements (unaudited).

Table of Contents

IMEDICOR, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

March 31, 2012

1. BASIS OF PRESENTATION

iMedicor, Inc., formerly Vemics, Inc. (the “Company”), builds portal-based, virtual work and learning environments in healthcare and related industries. Our focus is twofold: iMedicor, our web-based portal which allows Physicians and other healthcare providers to exchange patient specific healthcare information via the internet while maintaining compliance with all Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) regulations. The iMedicor portal is called SocialHIE (Health Information Exchange), and includes its ClearLobby technology. ClearLobby is our web-based portal adjunct which provides for direct communications between pharmaceutical companies and physicians for the dissemination of information on new drugs without the costs related to direct sales forces. Our solutions allow physicians to use the internet in ways previously unavailable to them due to HIPAA restrictions to quickly and cost-effectively exchange and share patient medical information and to interact with pharmaceutical companies and review information on new drugs offered by these companies at a time of their choosing. Our second focus is consulting with Medical Practices and Dental Practices to assist them in becoming “Meaningful Use” compliant and positioning these practices to receive the Federal Incentive funds to underwrite the transition from a paper to an electronic health records system. iMedicor began this service as an official agent of the NJ-HITEC / REC project working with primary care practices. Recently, iMedicor has expanded into specialists and dental practices.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted principles in the United States for full year financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Operating results for the three and nine month period ended March 31, 2012, are not necessarily indicative of the results that may be expected for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto that are included in the Company’s Form 10-K for the fiscal year ended June 30, 2011.

2. GOING CONCERN

From inception through March 31, 2012, the Company had devoted substantially all of its efforts to research and development of its technologies, acquisition of equipment and raising capital. The Company has incurred operating losses to date and has an accumulated deficit of approximately $48,227,000 and $46,235,000 at March 31, 2012 and at June 30, 2011, respectively. The Company’s activities have been primarily financed through convertible debentures and private placements of equity. The Company intends to raise additional capital through the issuance of debt or equity securities to fund its operations. The financing may not be available on terms satisfactory to the Company, if at all. No formal commitments or arrangements to advance or loan funds to the Company or repay any such advances or loans exist. There is no legal obligation for either management or significant stockholders to provide additional future funding.

3. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

4. NET EARNING (LOSS) PER SHARE

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period, less shares subject to repurchase. Diluted net loss per share reflects the potential dilution of securities by adding other common stock equivalents, including stock options, shares subject to repurchase, warrants and convertible notes to the weighted-average number of common shares outstanding for a period, if dilutive. All potentially dilutive securities have been excluded from the computation, as their effect is anti-dilutive.

Table of Contents

5. WARRANTS

As of March 31, 2012, the Company has issued warrants to purchase shares of Common Stock reserved for issuance upon exercise to various shareholders and service providers according to the schedule below:

No. Shares
Issuable on Exercise		Expiration		Exercise Price
	4,000,000		2013	$	0.04
	4,840,000		2013	$	0.03
	8,800,000		2014	$	0.03
	16,160,000		2013 – 2015	$	0.05

Management has reserved the right to redeem the warrants at $.10 per warrant if there is a subsequent initial public offering and market value per share meets certain levels.

6. TECHNOLOGY AND MEDICAL SOFTWARE

The Company has capitalized all acquisition costs associated with the acquisition of NuScribe Inc. In addition, we have elected to capitalize all related development costs associated with the completion of the iMedicor portal, which was included in the asset purchase of Nuscribe. The iMedicor portal was launched in late October 2007 and we have begun to amortize its cost on a straight-line basis over 60 months. Amortization expenses were $2,056,033 for the year ended June 30, 2011. The Company accounts for impairment of technology assets in accordance with recently issued and adopted accounting pronouncements, which require that technology with indefinite useful lives should be amortized, but also be tested for impairment at least annually at the reporting unit level. If impairment exists, a write-down to fair value (normally measured by discounting estimated future cash flows) is recorded. Intangible assets with finite lives are amortized primarily on a straight-line basis over their estimated useful lives and are reviewed for impairment. The Company has evaluated the technology and medical software for impairment as of June 30, 2011 for and has determined that the asset be impaired by $854,094.

	3/31/2012		6/30/2011
Technology and medical software	$	10,238,894	$	10,238,894
Less: Accumulated Amortization		8,120,906		7,245,886
Less: Impairment as of June 30, 2011		854,094		854,094

	$	1,263,894	$	2,138,914

7. SHORT TERM NOTES PAYABLE

Terms of convertible debentures

Amount outstanding		Interest Rate			Conversion Features
$	150,000		17.98	%	convertible into common shares at $0.45 per share
	120,155		8.00	%	convertible into common shares at $0.03 per share
	233,575		15.00	%	convertible into common shares at $0.05 per share
	58,821		8.00	%	convertible into common shares at $0.05 per share
$	562,551	Total

Table of Contents

Terms of the notes payable vary from 0% to 18% interest.

		3/31/2012
Company	$	2,504,008
Individual – Former Director		384,613
Individual		318,459
Trust		15,000
Individual – Former Director		10,000
Total	$	3,232,160

8. REVENUE

The Company has recorded income in the quarter ended March 31, 2012 from Mass Mutual Insurance in the amount of $65,000. Mass Mutual has refused to pay citing unenforceable contracts. iMedicor has instituted legal proceedings against Mass Mutual. The company has taken an allowance for bad debt relating to this receivable of 26% on the gross amount for the quarter; however the attorneys representing the company have indicated that the entire amount should be collectable.

9. SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through May 30, 2012, the date the accompanying financial statements were issued and have found no material events to report.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements made in this Quarterly Report on Form 10-Q, including without limitation this Management's Discussion and Analysis of Financial Condition and Operations, other than statements of historical information, are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements may sometimes be identified by such words as "may," "will," "expect," "anticipate," "believe," "estimate" and "continue" or similar words.

We believe that it is important to communicate our future expectations to investors. However, these forward-looking statements involve many risks and uncertainties, including the risk factors disclosed under the heading “Risk Factors” included in the Company's Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 22, 2012. Our actual results could differ materially from those indicated in such forward-looking statements as a result of certain factors. We are under no duty to update any of the forward-looking statements after the date of this Report on Form 10-Q to conform these statements to actual results.

Overview

The Company has built a portal-based, virtual work, learning and communication/collaboration environment for healthcare and related industries called iMedicor. Our primary focus shifted with our development of iMedicor, over 4 years ago. The portal has been in active use by physicians for approximately 3 1/2 years. iMedicor has developed its Network to include “interoperability” or the ability to securely transport and exchange, electronically, all forms of medical documentation between the vast array of disparate healthcare systems. One of the key components of the Federal “Meaningful Use” guidelines to be eligible for stimulus funds is interoperability. iMedicor has solved that problem with its HIPAA compliant, interoperable communications network, now referred to as iMedicor’s SocialHIE.

The iMedicor Portal was initially launched in October of 2007. In February of 2009 we launched version 2.0 of the Portal with completely redesigned functionality and security. During the redesign phase we focused less on increasing membership and more on working with a core group of physician members to address functionality within the site and make recommended changes for the launch of the 2.0 version. Last fiscal year the subscription model for iMedicor switched from a free service for all users to a $24.95 per month subscription service per physician user, with reduced rates for administrative staff within a physician’s office. As part of the shift we offered all existing members as well as new members, a sixty-day trial period at no cost. The percentage of users who agreed to convert from our free service to paying was not what we had hoped at less than 10%. Therefore, we are currently revamping the cost structure and our membership acquisition efforts. Rather than market ourselves as a stand-alone solution, we are partnering with EHR network, insurance, clearinghouses, PPO’s, MCO’s and other complimentary technology companies that have established membership bases and paying users, to offer a more robust and complete solution.

Currently the company has several pilots running with partners, that if successful could evolve into a boost in paying membership to approximately 40,000 members by the end of calendar 2012, representing gross revenues to iMedicor of approximately $800,000 per month, representing more than 5 times our current cash needs. There are several more relationships that the company is in the development stage of now which could boost that number dramatically As we build this paying customer base over time, the Company has also initiated a new line of revenue generating business in conjunction with the State of New Jersey HITEC, a Regional Extension Center of the Health Information Technology for Economic and Clinical Health Act, or the "HITECH Act". Among other things, the HITECH Act provides federal incentive dollars to physicians adopting EMR systems prior to the federally mandated 2014 deadline. The Company is acting as a health IT consultant with NJ-HITEC in its efforts to promote meaningful use of Electronic Health Records among New Jersey-based providers. In the quarter ended March 31, 2012 the company generated approximately $71,000 in revenue from the NJ HITEC program. It is the company’s intention to develop more of these programs with other regional HITEC authorities. The HITEC project participation is becoming a viable stepping stone to further the iMedicor SocialHIE deployment.

As of March 31, 2012, we require approximately $150,000 per month to fund our operations. This amount has consistently decreased over the past several quarters and the company continues to consolidate its operations until such a time as revenue is able to exceed operational costs, This amount is expected to increase as we expand our sales and marketing efforts and continue to develop new products and services; however we do not have the funds available to increase our operations or to pay off prior debts to date. As of the date of this report the Company has reduced operations to a bare minimum to conserve what cash is available and costs have been further reduced from the $150,000 per month needed.

Table of Contents

We are currently seeking up to $4,000,000 in capital through a private placement of preferred stock, and have received a signed subscription agreement from an accredited investor for $2,000,000, payable in two tranches of $1,000,000 however, due to delays in finalizing other initiatives outside of iMedicor, the investor has not to date been able to make the first tranche payment. As of the date of this report no funds have been received in association with the above subscription agreement and we have been reliant on two of the Company’s major investors and its employees and management to fund critical operational costs, however not all costs have been able to be met. For example, in the quarter ended December 30, 2011 the company was only able to meet approximately 53% of its payroll obligations to its staff, and that trend has continued into the current quarter, with the company having met less than 1% of its payroll obligations to date in calendar 2012. While we are seeking funding, if revenue increases to a point where we are able to sustain ourselves and increase our budget to match our growth needs, we may significantly reduce the amount of investment capital we are seeking. The exact amount of funds raised and revenue generated will determine how aggressively we can grow and what additional projects we will be able to undertake.

Critical Accounting Policies and Estimates

Our discussion and analysis of financial condition and results of operations are based upon the condensed consolidated financial statements included in this Form 10-Q for the quarterly period ended December 30, 2011, which have been prepared in accordance with generally accepted accounting principles as recognized in the U.S. The preparation of these financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and disclosure of contingent assets and liabilities. Our estimates include those related to revenue recognition, the valuation of inventory, and valuation of deferred tax assets and liabilities, useful lives of intangible assets and accruals. We base our estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

Results of Operations

Three months ended March 31, 2012 Compared to Three Months Ended March 31, 2011

The following table sets forth for the periods indicated the percentage of total revenues represented by certain items reflected in our statements of operations:

	Three Months Ended March 31
	2012			2011
	(unaudited)			(unaudited)
Revenues	$	284,941		$	133,996

Operational General and Administrative Expenses		552,092			477,759
Depreciation and amortization		291,673			512,853
Total Expenses		843,765			990,612
Loss before other income (expense)	$	(558,824	)	$	(856,616	)

Revenues

The Company's revenues for the three months ended March 31, 2012 increased by approximately 209% to $284,941 from $133,996 in the three months ended March 31, 2011. The increase in revenue is due largely to 4 items:

1.	There is a new line of revenue generating business in conjunction with the State of New Jersey HITEC.

2.	There is a new line of revenue generating business in relation to the Hamilton Dental Associates group (see just below for details).

3.	On February 21, 2012, there was a settlement between NaviNet, Inc. and iMedicor, Inc. (on December 9, 2008, entered into a Co-Marketing agreement) that resolved forever the claims related to all disputes and as a result NaviNet, Inc. paid iMedicor, Inc. $100,000.

Table of Contents

Revenues – (continued)

The Company recorded $65,000 of Revenues for this quarter per the contract with Mass Mutual. The Company increased its allowance for doubtful accounts from 20% to 26% of the outstanding receivables associated with Mass Mutual. The Company is in litigation with Mass Mutual in regard to the three year contract. At this time, counsel has indicated that both parties are to enter discovery in June 2012. Counsel has also indicated that there is not sufficient information to determine the outcome of this matter.

The Company has entered into a contract with a group named Hamilton Dental Associated dated January 25, 2012 to provide them the consulting guidance to become eligible for Medicaid EHR (Electronic Health Reporting) Incentive Programs. One of the primary purposes of the Federal government promoting these incentive programs is get all medical and dental practices that service Medicare and Medicaid to use electronic reporting systems so that the government can better monitor the servicing procedures and eliminate fraud.

The Medicare and Medicaid EHR Incentive Programs will provide incentive payments to eligible professionals, eligible hospitals and critical access hospitals (CAHs) as they adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

If the group Hamilton Dental Associates qualifies as a practice in which at least 30% of the patients are Medicaid eligible they stand to receive from the Federal Incentive EHR Program as follows:

·	Year 1 - $21,250 per individual eligible provider

·	Years 2-6 - $8,500 per year per individual eligible provider

·	iMedicor is to receive 10% of the incentive fees received each year

Upon signing of the contract the Company earned an upfront consulting fee of $60,000 payable in 3 monthly installments of $20,000. This fee was earned as a result of the upfront efforts and startup costs incurred by the Company in getting Hamilton Dental Associates in place to qualify as Medicaid qualified provider.

Operational, General and Administrative Expenses

Operational, general and administrative expenses for the quarter ending March 31, 2012 increased to $552,092 from $477,759, for the quarter ending March 31, 2011 or approximately 13%. This minor increase reflects the Company’s continued effort to consolidate operations until such time that it can sustain growth through revenue generation.

Depreciation and Amortization

Depreciation and Amortization expenses decreased to $291,673 for the quarter ended March 31, 2012 from $512,853, for the quarter ending March 31, 2011. On June 30, 2011 the company tested its medical technology and software for impairment and found it to be impaired. The current depreciation number reflects depreciation after impairment, with a new finite life of the asset based on current revenue generating contracts in hand.

Loss from Operations

Income (loss) from operations for the quarter ended March 31, 2012 totaled ($558,824) compared to ($856,616) for the quarter ended March 31, 2011 or a decrease of approximately 35%. The decrease in loss from operations for the quarter ended March 31, 2012 is primarily due to the increase in revenue from a new line of business, the company’s continued consolidation of operations and decrease in amortization of our technology.

Table of Contents

Results of Operations

Nine months ended March 31, 2012 Compared to Nine Months Ended March 31, 2011

The following table sets forth for the periods indicated the percentage of total revenues represented by certain items reflected in our statements of operations:

	Nine Months Ended March 31
	2012			2011
	(unaudited)			(unaudited)
Revenues	$	637,295		$	477,119

Operational General and Administrative Expenses		1,350,636			1,200,623
Depreciation and amortization		876,364			1,545,506
Stock issued for fees and services		-			545,309
Total Expenses		2,227,000			3,291,438
Loss before other income (expense)	$	(1,589,705	)	$	(2,814,319	)

Revenues

The Company's revenues for the nine months ended March 31, 2012 increased by approximately 32% to $637,275 from $477,119 in the nine months ended March 31, 2011. The increase in revenue is due largely to 3 items:

1.	There is a new line of revenue generating business in conjunction with the State of New Jersey HITEC.

2.	There is a new line of revenue generating business in relation to the Hamilton Dental Associates group.

3.	On February 21, 2012, there was a settlement between NaviNet, Inc. and iMedicor, Inc. (on December 9, 2008, entered into a Co-Marketing agreement) that resolved forever the claims related to all disputes and as a result NaviNet, Inc. paid iMedicor, Inc. $100,000.

Operational, General and Administrative Expenses

Operational, general and administrative expenses for the nine months ended March 31, 2012 increased to $1,350,636, from $1,200,623 for the nine months ended March 31, 2011 or approximately 12%. This increase is attributed to the company expanding the sales force rather than electing to consolidate operations. In nine months ended March 31, 2011 the company issued stock valued at $545,309 as fees for services. In the same period in 2012 it issued none.

Table of Contents

Depreciation and Amortization

Depreciation and Amortization expenses decreased to $876,364 for the nine months ended March 31, 2012 from $1,545,506, for the nine months ended March 31, 2011. On June 30, 2011 the company tested its medical technology and software for impairment and found it to be impaired. The current depreciation number reflects depreciation after impairment, with a new finite life of the asset based on current revenue generating contracts in hand

Loss from Operations

Income (loss) from operations for the nine months ended March 31, 2012 decreased by $1,224,614 to ($1,589,705) as compared to ($2,814,319) for the nine months ended March 31, 2011, or approximately 43%. The decrease in loss from operations for the nine months ended March 31, 2011 is primarily due to the increase in revenue from a new line of business, the company’s continued consolidation of operations and the significant decrease in amortization of our technology.

Liquidity and Capital Resources

Cash and cash equivalents were $29,523 at March 31, 2012 compared to $18,208 at June 30, 2011.

Net cash used in operating activities was $353,799 for the nine months ended March 31, 2012 as compared to $1,213,760 for the nine months ended March 31, 2011, representing a decrease of approximately 71%. This is attributed to an increase in revenues and a decrease in operating expenses.

Net cash used in investing activities was $-0- for the nine months ended March 31, 2012 as compared to cash used by investing activities of $55,000 for the nine months ended March 31, 2011.

Net cash provided in financing activities was $365,114 for the nine months ended March 31, 2012 as compared to net cash used by financing activities of $1,183,116 for the nine months ended March 31, 2011, or a decrease of approximately 69%. This reflects the difficulties as a smaller reporting company in raising capital in the current market.

Due to our serious cash position and the lack of adequate sales revenue as the iMedicor portal has not yet begun to generate any significant sales, the Company has continued to reduce costs where possible, including eliminating non-essential staff positions and eliminating non-essential operating costs as well as reducing salaries and benefits of current employees.

The Company continues to operate at a loss and is projected to do so until the fourth quarter of this fiscal year. The Company is reliant, therefore, on raising capital through equity investments and/or debt instruments to maintain operations. The Company is actively engaging in fundraising efforts to increase its current level of operations.

Off-Balance Sheet Arrangements

The Company does not have any off-Balance Sheet Arrangements that are likely to have a current or future affect on our financial condition, revenues, results of operations, liquidity, or future effect on capital expenditures.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

N/A.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive and Chief Financial Officers, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive and Chief Financial Officers concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective so that that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management in order to allow for timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Management has determined that, as of March 31, 2012, there were material weaknesses in both the design and effectiveness of our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

The deficiencies in our internal controls over financial reporting and disclosure controls and procedures are related to the lack of segregation of duties due to the size of our accounting department, and limited enterprise resource planning systems. When our financial position improves, we intend to hire additional personnel and implement enterprise resource planning systems required to remedy such deficiencies.

(b) Changes in Internal Controls over Financial Reporting

There were no changes in our internal controls over financial reporting (as defined in Exchange Act Rule 13a-15(f)) during the three-months ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART 2: OTHER INFORMATION

ITEM 5. OTHER INFORMATION

ITEM 6. EXHIBITS

4.1		Secured Convertible Promissory Note of the Company dated April 18, 2009*

4.2		Modification Agreement dated December 31, 2010**

4.3		Secured Convertible Promissory Note dated December 31, 2010**

4.4		Series “A” Preferred Stock Description**

4.5		Series “B” Preferred Stock Subscription Agreement**

4.6		Series “B” Preferred Stock Description**

31.1		Certification of the President and Chief Executive Officer pursuant to Rule 13a-14(a).

31.2		Certification of the Chief Financial Officer and Treasurer pursuant to Rule 13a-14(a).

32		Certification of the President and Chief Executive Officer and Chief Financial Officer and Treasurer pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002.

* Incorporated by reference to the Company’s 8-K filing dated May 5, 2009

** Incorporated by reference to the Company’s 8-K filing dated January 18, 2011

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMedicor, Inc. (Registrant)

Date: May 30, 2012	By:	/s/ Fred Zolla
		Fred Zolla
		President and Chief Executive Officer (Principal Executive Officer)

Date: May 30, 2012	By:	/s/ Fred Zolla
		Interim Chief Financial Officer (Principal Accounting Officer)

Table of Contents